
Nuvation Bio Hits New 52-Week High of $5.55, Up 81.38%
2025-10-30 18:53:16Nuvation Bio, Inc. has achieved a new 52-week high of USD 5.55, marking an 81.38% increase over the past year. With a market capitalization of USD 1,198 million, the company faces challenges, including a negative return on equity and a notable debt-to-equity ratio, while navigating the competitive biotechnology sector.
Read More
Nuvation Bio Hits Day High with 10.48% Surge, Showcases Strong Intraday Performance
2025-10-27 17:43:14Nuvation Bio, Inc. has seen notable stock performance, with significant increases over various time frames, including a 110.87% return over the past year. Despite facing challenges such as negative results in recent quarters and declining profits, the company's market capitalization stands at approximately USD 1,198 million.
Read More
Nuvation Bio Hits New 52-Week High of $4.87, Up 67%
2025-10-27 17:04:13Nuvation Bio, Inc. has achieved a new 52-week high, reflecting a strong one-year performance that significantly outpaces the S&P 500. With a market capitalization of USD 1,198 million, the company faces challenges, including negative return on equity and a high debt-to-equity ratio, while pursuing a growth-focused strategy.
Read More
Nuvation Bio Hits New 52-Week High of $4.32, Up 43.1%
2025-10-23 17:14:54Nuvation Bio, Inc. has achieved a new 52-week high, reflecting a strong one-year performance that surpasses the S&P 500. With a market capitalization of USD 1,198 million, the company faces challenges in financial metrics, including negative return on equity and a high price-to-book ratio, amidst a competitive biotechnology landscape.
Read More
Nuvation Bio Hits Day High with 15.63% Surge in Strong Intraday Performance
2025-10-01 16:22:46Nuvation Bio, Inc. has seen notable stock activity, with a significant increase on September 30, 2025. The company has demonstrated strong weekly and monthly performance, alongside a year-to-date rise. Despite facing challenges with consecutive negative quarterly results, its one-year return reflects resilience in the competitive pharmaceuticals sector.
Read More
Nuvation Bio Stock Hits Day Low of $3.00 Amid Price Pressure
2025-09-26 14:27:30Nuvation Bio, Inc. has faced a notable stock decline, reaching an intraday low amid a challenging trading environment. Despite a positive monthly performance, the company's long-term outlook is concerning, with significant declines over five years and ongoing negative quarterly results, raising valuation concerns.
Read More





